Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03478462 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
A Phase 1 study of Neuroblastoma and Osteosarcoma, sponsored by Cellectar Biosciences.
- Active
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 8
- Study locations
NCT03478462 is a Phase 1 study of Neuroblastoma and Osteosarcoma that is active but no longer recruiting, run by Cellectar Biosciences. The registered enrollment target is 30 participants, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (87% lower). The trial reports 8 study locations across 8 states.
The verdict
NCT03478462, a Phase 1 study of Neuroblastoma and Osteosarcoma, is active but no longer recruiting, sponsored by Cellectar Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 8
- Study locations
Study Summary
The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment options with curative potential.
Conditions Studied
Interventions
- DRUG CLR 131
Study Locations (8)
California
- Lucile Packard Children's Hospital - Palo Alto
New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- Duke University - Chapel Hill
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Texas
- Texas Children's Hospital - Houston
Wisconsin
- University of Wisconsin Hospital and Clinics - Madison
New South Wales
- Children's Hospital at Westmead - Westmead
Ontario
- Hospital for Sick Children - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2019-04-30 |
| Est. Completion | 2027-02-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03478462
The ClinicalTrials.gov registry entry for NCT03478462 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 239-participant average among 94 other Neuroblastoma trials with a reported enrollment target (87% lower). The listed sponsor is Cellectar Biosciences, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Neuroblastoma appearing as the primary indexed condition, and to 1 intervention - of which CLR 131 is the first listed.
NCT03478462 reports 8 study locations spanning 8 distinct geographic areas - top geographies include California, New York, North Carolina.
Frequently Asked Questions
What is clinical trial NCT03478462 about?
NCT03478462 is a clinical study titled "Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas". The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment options with curative potential.
What is the current status of trial NCT03478462?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2019-04-30. Estimated completion is 2027-02-25.
What conditions does trial NCT03478462 study?
This clinical trial studies the following conditions: Neuroblastoma, Osteosarcoma, Rhabdomyosarcoma, Ewing Sarcoma, Pediatric Solid Tumor.
What interventions are being tested in trial NCT03478462?
The interventions under investigation include: CLR 131 (DRUG).
Who is sponsoring clinical trial NCT03478462?
This trial is sponsored by Cellectar Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03478462 being conducted?
This trial has 8 study locations across California, New York, North Carolina, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
RECRUITING · Phase 1
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
RECRUITING · Phase 1
-
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RECRUITING · Phase 1
-
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.